Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of -14.29% and +5.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?